A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults
Latest Information Update: 20 May 2024
At a glance
- Drugs VBI 2902 (Primary) ; Aluminium phosphate
- Indications COVID 2019 infections
- Focus Adverse reactions; Proof of concept
- Sponsors VBI Vaccines
Most Recent Events
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 18 Jul 2022 Number of treatment arms decreased from 6 to 5, by the removal of Experimental: Phase 1b, Group G6 arm.
- 18 Jul 2022 Planned End Date changed from 1 Nov 2022 to 1 Dec 2022.